Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record.

Escort aptamers: a delivery service for diagnosis and therapy

Open access
Hicke, Brian J., Stephens, Andrew W.·2000·Journal of Clinical Investigation

Abstract

In 1990, the discovery of aptamers by Tuerk and Gold (1) and subsequently by Ellington and Szostak (2) spawned significant interest within academia and industry.Aptamers have quickly become valuable research tools (3-5).More than that, a therapeutic aptamer (6) has entered clinical evaluation just eight years after the inception of the technology.While aptamers have built inroads into therapeutic applications, they may also become important in vitro diagnostic tools (7).Here, we discuss a new development: the use of "escort aptamers" as targeting agents for in vivo diagnosis and therapy.Instead of directly interrupting a disease process, as would a function-blocking aptamer, escort aptamers are designed to deliver radionuclides, toxins, or cytotoxic agents to diseased tissue.Specifically, we focus on the delivery of benign radionuclides for in vivo diagnosis of disease.For discussion of function-blocking aptamers, see White et al., this Perspective series (8). Aptamers and antibodiesThe advent of monoclonal antibodies in 1974 brought to mind Paul Ehrlich's turn-of-the-century insight that molecules could serve as "magic bullets" that home to pathological organisms with precision (http://nobel.sdsc.edu/medicine/laureates/1908/ehrlich-bio.html).Indeed, the high affinity and specificity of antibodies provide some of the key properties in Ehrlich's concept.Despite some successes in tissue targeting, antibodies are saddled with a fundamental disadvantage: their large size (∼155 kDa) results in slow tissue penetration and long blood residence.For example, in clinical settings where an antibody is coupled to a cellkilling radionuclide, this long circulation half-life leads to bone marrow toxicity that limits the permissible dose (9).To decrease blood half-life while maintaining target specificity, a second generation of smaller antibody fragments has been designed (10,11).Antibody pretargeting strategies also show promise (12-14), and small peptides can have excellent pharmacokinetic profiles (15).However, many approaches are limited by complexity of clinical protocols, paucity of available targeting molecules, low-

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci11324

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 169

Metadata

Authors
Hicke, B. J., & Stephens, A. W.
Venue
Journal of Clinical Investigation
Published
2000-10-15
Volume
106
Issue
8
Pages
923-928
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2071745634
Cited by
169
References
0
FWCI
5.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Escort aptamers: a delivery service for diagnosis and therapy. https://app.cochat.ai/papers/10.1172/jci11324
The paper
Hicke, B. J., & Stephens, A. W. (2000). Escort aptamers: a delivery service for diagnosis and therapy. Journal of Clinical Investigation. https://doi.org/10.1172/jci11324

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.